Skip to main content
. Author manuscript; available in PMC: 2021 Dec 14.
Published in final edited form as: Pediatr Blood Cancer. 2020 Mar 24;67(6):e28222. doi: 10.1002/pbc.28222

FIGURE 1.

FIGURE 1

Event-free survival to regorafenib across all PDX models. Regorafenib induced significant improvements in event-free survival (EFS) compared to control in 100% (10/10) of the sarcoma models tested with significantly prolonged time to event in all models (P < .05). Mice still alive at the conclusion of the experiment, but whose tumors had not yet quadrupled are considered right-censored and are indicated by a plus sign (+)